Health

Outsmarting AMR: Economist Impact at the 2021 World Anti-Microbial Resistance Congress

November 18, 2021

Global

Outsmarting AMR: Economist Impact at the 2021 World Anti-Microbial Resistance Congress

November 18, 2021

Global
Amanda Stucke

Principal, Health Policy & Insights, Economist Impact

Amanda is a principal in the Health Policy & Insights Practice at Economist Impact, based in London. She collaborates within a global, multidisciplinary team to lead and deliver robust, high-visibility research and analysis programs across the public and private global health ecosystem. Her main area of focus is unlocking the potential of health to drive growth and development at the population level, including across topics such as ageing, healthspan and longevity; health security; AMR; health investment and finance; workforce wellbeing; and social and commercial determinants of health.

Amanda brings approaches such as systems thinking and design, strategic foresight, policy and comparative analysis, economic modelling, decision science, and translational research and writing to bridge the gap between evidence and practice. Prior to joining Economist Impact, she led a major health innovation initiative for the Surgeon General of the US Navy, and executed an economic study of cancer screening with the Ministry of Health in Greenland. Amanda has led and contributed to other global health initiatives in countries such as Brazil, Bangladesh and Haiti.

Amanda holds a masters degree in Health Policy & Clinical Practice from the Geisel School of Medicine at Dartmouth. She has also received training as a foresight practitioner from the School of International Futures.

Our health practice presents key insights at the 2021 World AMR Congress. Global leaders in the space came together on November 8th and 9th to discuss new innovations, partnerships and initiatives to address the global threat of AMR.

While much of the world’s attention was on the evolving covid-19 regulations and COP-26 winding down last week, members of our health practice participated in the World Anti-Microbial Resistance (AMR) Congress in Washington, DC. AMR, commonly referred to as the “silent tsunami”, is one of the biggest health security risks the world faces. As our supply of effective antibiotics dwindles, new resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases. 

The World AMR Congress brought together global leaders in medicine, innovators in technologies and treatments, patient advocates and academics, to tackle the challenges and opportunities we face in this space. As a conference chair, Amanda Stucke, Economist Impact senior manager and Americas regional lead opened day two of the congress with remarks on what makes AMR so unique: 

“it requires new ways of innovating and collaborating across traditionally siloed sectors of human and animal health, agriculture and climate. It provides an opportunity to break down barriers, both at the systems level and for individuals, promoting equity and access. Addressing AMR also means fixing problems in our systems that will impact so much more than just AMR, including how we collect data, how we put patients at the centre, prioritise our environment, and how we ensure that the right prevention, diagnostics and treatments reach the right patients, at the right time.” 

Michael Dillon, Economist Impact business development lead and David Humphreys, global head of the Economist Impact Health Practice, also led discussions at the congress. They focused on addressing AMR through collaboration between public and private sectors, and raising the importance of the patient voice in R&D and policy discussions. These sessions highlighted the complexities of AMR: it is a multi-faceted problem that requires a multi-faceted solution beyond any one sector or stakeholder to outsmart it. The congress also made clear that the need to take meaningful action to address AMR is urgent, as AMR mortality is estimated to outpace deaths from all cancers in our lifetimes. These actions must include a pursuit of a strengthened antibiotic pipeline, a steadfast commitment to the One Health approach, and economic and policy action that foster an effective enabling environment for progress. Economist Impact remains committed to being a global partner in supporting these actions in the fight against AMR globally. 

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week